{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Germany Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/de/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/de/healthcare/feed.json", "description": "Latest Healthcare company headlines from Germany, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:a2260ed65dc741a2045ed40e0f3fc2b0e05b22750b7e9cbbe9d58d2b25b76d49", "url": "https://finance.yahoo.com/video/luigi-mangione-pleads-guilty-us-175043898.html", "external_url": "https://finance.yahoo.com/video/luigi-mangione-pleads-guilty-us-175043898.html", "title": "Luigi Mangione Pleads Guilty in US Case Over CEO Killing", "content_text": "Luigi Mangione pleaded guilty in a federal case over the fatal shooting of UnitedHealth Group executive Brian Thompson in December 2024. View Comments", "date_published": "2026-08-14T17:50:43+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "UNH"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UNH", "name": "UnitedHealth Group Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/f72c163c-734b-4be4-bacc-7fc3aa9e96fb/"}]}}, {"id": "source:9213e54062b821c3fe4e7e5fd40f3eda5a94d37f2eea1851ea1d35b54532b91b", "url": "https://finance.yahoo.com/video/mangione-admits-killing-healthcare-ceo-174821220.html", "external_url": "https://finance.yahoo.com/video/mangione-admits-killing-healthcare-ceo-174821220.html", "title": "Mangione Admits to Killing Healthcare CEO Brian Thompson", "content_text": "Luigi Mangione pleaded guilty to federal stalking charges related to the fatal shooting of UnitedHealth Group Inc. executive Brian Thompson. Mangione admitted on Friday in New York federal court that he shot and killed Thompson on Dec. 4, 2024. He faces life in prison. Mangione's attorney, Karen Friedman Agnifilo, US Attorney for the Southern District Jamie McDonald and NYPD Police Commissioner Jessica Tisch all spoke outside the court. View Comments", "date_published": "2026-08-14T17:48:21+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "UNH"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UNH", "name": "UnitedHealth Group Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/f72c163c-734b-4be4-bacc-7fc3aa9e96fb/"}]}}, {"id": "source:a7e32986cac0d16c450dab2589dc0ebcf0cfb84777fbf47d7139a5263228d988", "url": "https://finance.yahoo.com/m/5d38b910-72a9-371f-9838-f00d13764cf5/pfizer-ceo-caps-post-earnings.html", "external_url": "https://finance.yahoo.com/m/5d38b910-72a9-371f-9838-f00d13764cf5/pfizer-ceo-caps-post-earnings.html", "title": "Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase", "content_text": "Three Pfizer insiders executed transactions directly on the heels of the drugmaker\u2019s second-quarter earnings report. Continue Reading", "date_published": "2026-08-14T17:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}, {"id": "source:0255478c1d6a1daa9aacd8e79c7f2c3be6c707552e7a68c1d719ffab92cbcba9", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOUTBrcnB6NEc5S0FXdmF2WHZoa2RMR2lzbS1fOVBTSTVaSGF5ZGJyOVFZT0Q5WFBBRzdHelNKeG1zVmFDekNfaVNfY25kRGxQaUFGUmFzY2dRa3NPcXZzZ05xeFBfd0JCUmxjR213WWY2TEw0U2V5ZWtEOFl1RFZHX3h5WWpNTmV3VUVOYXN2SGs3R24yZmRXOGFJYVZ3MFlSVEhqNVJNTFZOaXBtYnl1QVJnQmxUam5hZWQwa2hyRURwdWJNSFRiWDI1N0l1RGs?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOUTBrcnB6NEc5S0FXdmF2WHZoa2RMR2lzbS1fOVBTSTVaSGF5ZGJyOVFZT0Q5WFBBRzdHelNKeG1zVmFDekNfaVNfY25kRGxQaUFGUmFzY2dRa3NPcXZzZ05xeFBfd0JCUmxjR213WWY2TEw0U2V5ZWtEOFl1RFZHX3h5WWpNTmV3VUVOYXN2SGs3R24yZmRXOGFJYVZ3MFlSVEhqNVJNTFZOaXBtYnl1QVJnQmxUam5hZWQwa2hyRURwdWJNSFRiWDI1N0l1RGs?oc=5", "title": "Die Edwards-Lifesciences-Aktie steigt dank starker Q2-Dynamik und hoher Bewertung", "content_text": "Die Edwards-Lifesciences-Aktie steigt dank starker Q2-Dynamik und hoher Bewertung", "date_published": "2026-08-14T17:36:18+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "EWL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EWL", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/d182ff67-5fcd-48c1-9450-8975babb5883/"}]}}, {"id": "source:6fcd1f479fbad1c6889db3d873f005035108d3c3aad96cfd0f27b40e19d425d2", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNcTZWak9hWGxiM1N1UmhFUTU2SWFySVJseWRYYi0tRF9yNUNudXIxaWtBZ3VtU0J1Rm80SDF5TURDeFZmMFBHM2lGQjdDbUlNZjhjdHFScjZyYUtvanJPQmdsR3FpWTdPUW9qUjJ6LTZkSXpfdFlQOC05RlRTR1p5R3BpSm1ienJtY3dWR3hDbmZBY3psTzE0a1BXNkRYbHI2STVCd19YdWk1cTA5SDdYQ1JNbEtBdHF0SkY2d0dDbHlFbmxuUVpHWVNNY3c?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNcTZWak9hWGxiM1N1UmhFUTU2SWFySVJseWRYYi0tRF9yNUNudXIxaWtBZ3VtU0J1Rm80SDF5TURDeFZmMFBHM2lGQjdDbUlNZjhjdHFScjZyYUtvanJPQmdsR3FpWTdPUW9qUjJ6LTZkSXpfdFlQOC05RlRTR1p5R3BpSm1ienJtY3dWR3hDbmZBY3psTzE0a1BXNkRYbHI2STVCd19YdWk1cTA5SDdYQ1JNbEtBdHF0SkY2d0dDbHlFbmxuUVpHWVNNY3c?oc=5", "title": "Die Becton-Dickinson-Aktie profitiert von Gewinnanstieg und erh\u00f6hter Prognose", "content_text": "Die Becton-Dickinson-Aktie profitiert von Gewinnanstieg und erh\u00f6hter Prognose", "date_published": "2026-08-14T16:50:07+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "BOX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BOX", "name": "Becton, Dickinson and Company", "sentiment_url": "https://sharemaestro.com/sentiment/f5080ec9-f7c4-4462-8c86-3a0fe19a51c4/"}]}}, {"id": "source:3d2b95b95e91585aab83cab8182fc725b8b90acb95a0866a27394d1280ac023b", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPMGxSMV9rVGpXTU1SNUdvaUZBdzdjazdQbUJ4aS1yY0Y5OVVmdDRiRlBTZngzR2ZCZ21KS2pKUjdYc0JnSEVuZHZwRGt4VXZyZm9QUUFOaUVxeGpNQzh3d3NKN2x1U0lvMW15YXlSaXkwX1ZlMUNWMUMtNUgzZU43LTRIWWJYRThmSU5TQjBZblduT202OGtONVFOZW5YZjRIcjdRY2NnWElaNTZCWE4zZmN2V202VmREU19sVldlNlJLUTduWHgtV2RCNGhpUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPMGxSMV9rVGpXTU1SNUdvaUZBdzdjazdQbUJ4aS1yY0Y5OVVmdDRiRlBTZngzR2ZCZ21KS2pKUjdYc0JnSEVuZHZwRGt4VXZyZm9QUUFOaUVxeGpNQzh3d3NKN2x1U0lvMW15YXlSaXkwX1ZlMUNWMUMtNUgzZU43LTRIWWJYRThmSU5TQjBZblduT202OGtONVFOZW5YZjRIcjdRY2NnWElaNTZCWE4zZmN2V202VmREU19sVldlNlJLUTduWHgtV2RCNGhpUQ?oc=5", "title": "Die Abbott-Laboratories-Aktie legt nach starker Q2-Guidance moderat zu", "content_text": "Die Abbott-Laboratories-Aktie legt nach starker Q2-Guidance moderat zu", "date_published": "2026-08-14T15:49:44+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:6c58c8898d3de5e153c68c94344dd2ae2cafa61a79c8bb4625396eed37e5f061", "url": "https://finance.yahoo.com/healthcare/articles/elevance-health-elv-6-8-153003420.html", "external_url": "https://finance.yahoo.com/healthcare/articles/elevance-health-elv-6-8-153003420.html", "title": "Elevance Health (ELV) Up 6.8% Since Last Earnings Report: Can It Continue?", "content_text": "It has been about a month since the last earnings report for Elevance Health (ELV). Shares have added about 6.8% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Elevance Health due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Elevance Health, Inc. before we dive into how investors and analysts have reacted as of late. ELV Beats Q2 Earnings Estimates on Higher CarelonRx Product R", "date_published": "2026-08-14T15:30:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "A58"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "A58", "name": "Elevance Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1d5bf969-2db0-49f7-bd02-ec9dd329dcd9/"}]}}, {"id": "source:99f2dd125e62553289402f86f8b90c94686eb3f963ecddfd879c9f9900b4be9e", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOWmJIemtIMG0zSDJ3WHFXTm9hbjREZGtxRXQ4d2ZxYldES1ZZdjVMRkxEVmVvS2NzcEpTSGtPUS1kZll4ZHR1VWlfNHZlaEJvcUZ1N2RBWm9IcFRNTy10Ym9GN0dNb0dOUkJHZjh0allLMWJXWlA3Wl9YQjUwLWNyWFA0R3BNejlGblJ3bHRaV0U1cHRnR2RRakViUE1tZDFnc1E0OVNpQmZhREhhZEFxZ1h5Q0dUazZLM0xKRFpSTQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOWmJIemtIMG0zSDJ3WHFXTm9hbjREZGtxRXQ4d2ZxYldES1ZZdjVMRkxEVmVvS2NzcEpTSGtPUS1kZll4ZHR1VWlfNHZlaEJvcUZ1N2RBWm9IcFRNTy10Ym9GN0dNb0dOUkJHZjh0allLMWJXWlA3Wl9YQjUwLWNyWFA0R3BNejlGblJ3bHRaV0U1cHRnR2RRakViUE1tZDFnc1E0OVNpQmZhREhhZEFxZ1h5Q0dUazZLM0xKRFpSTQ?oc=5", "title": "Die Thermo-Fisher-Aktie legt nach starken Quartalszahlen zu", "content_text": "Die Thermo-Fisher-Aktie legt nach starken Quartalszahlen zu", "date_published": "2026-08-14T14:31:53+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:bf9dca1d6d711e2dff061db7dc8e6ed04f11394260bbbbfa2e8d68cee7e20980", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxORnhfZmdHRkhIMFpsWFJwcjVEbzVIcjFaU3lJdEx3WVZYUWd0c2xEa3NHVFkwNi1XZjg3RGtqZUNpazBBTTkzWE9VSkU2aDJPQ3dXS0xtTDRISWZxMXB5OEdpZnl6U2p2MGZ5cHdyZ3VvRHhsVU8ydVM4OFk5NHloMjFnYzUwSGRqMHRLbGJyajNYUmlUc2o3RTNQb3ZwdTB6OU5mVEVMMUhCR0p1STJtWkRmNjZ3d19FSlpYLTByaHBHN193YlBFalhuVFcxQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxORnhfZmdHRkhIMFpsWFJwcjVEbzVIcjFaU3lJdEx3WVZYUWd0c2xEa3NHVFkwNi1XZjg3RGtqZUNpazBBTTkzWE9VSkU2aDJPQ3dXS0xtTDRISWZxMXB5OEdpZnl6U2p2MGZ5cHdyZ3VvRHhsVU8ydVM4OFk5NHloMjFnYzUwSGRqMHRLbGJyajNYUmlUc2o3RTNQb3ZwdTB6OU5mVEVMMUhCR0p1STJtWkRmNjZ3d19FSlpYLTByaHBHN193YlBFalhuVFcxQQ?oc=5", "title": "Die Bristol-Myers-Squibb-Aktie profitiert von FDA-Zulassung und solider Prognose", "content_text": "Die Bristol-Myers-Squibb-Aktie profitiert von FDA-Zulassung und solider Prognose", "date_published": "2026-08-14T14:25:47+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:003901eac9af269cec5562f97186cf7b5459ffc496c54fb72170db2160dfcb70", "url": "https://finance.yahoo.com/markets/stocks/articles/eurofins-scientific-director-pdmr-shareholding-131300537.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/eurofins-scientific-director-pdmr-shareholding-131300537.html", "title": "Eurofins Scientific: Director/PDMR Shareholding", "content_text": "LUXEMBOURG, August 14, 2026--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (\"PDMR\"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytic", "date_published": "2026-08-14T13:13:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ESF0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ESF0", "name": "Eurofins Scientific SE", "sentiment_url": "https://sharemaestro.com/sentiment/0b5b97e2-6f0c-4512-9962-82c5c6aad9b2/"}]}}, {"id": "source:6f3ad19d45a6717c24f32fbbfc13925fbc5ddd56cad0c94e00daaf0deab9b172", "url": "https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html", "title": "Amgen (AMGN) Stock Looks Undervalued With A 37% Fair Value Gap", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Amgen stock has delivered strong gains over the past five years, yet the current share price sits at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model, while broader valuation checks point to a more mixed picture. Amgen has returned 116.3% over the past five years, which puts more weight on whether the current valuation still leaves room for an attractive long term outcome. Plans to open a", "date_published": "2026-08-14T12:09:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "AMG"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AMG", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/168fd802-fccc-4e50-a2bc-bc539b6e35a1/"}]}}, {"id": "source:feb4c10773207b089470a45f64ed6c862c294f24a43dcb044c603c039d23c4d0", "url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "external_url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "title": "Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains", "content_text": "While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading", "date_published": "2026-08-14T12:00:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:ac904f1c46ae1d07a76c2eb67def2f0c2e33c3bdf87a7858ec6a336d1dc5211f", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQbEl3NjBGUHVWaXh5djVmMUlYNU9OYkNjbzB2SHdtTjBFYUpIMGR3WVV4YlF1TTVHTkF2eDhrV1h5TVpuYWloSmRkcWtYNDczdThSOVlYV1p6M0ZWczhFcDdtNTZoMDZhZHlobGo2ZEhmZlNTMTRiV2ZkcFlZeUpLa1RvcVNQbmNwZ3lIQ3ZueW82QVpVLTROaUFta054ejhRZWZNZXA2TDZic1lGWmFiemJmZFpDY3phc0tUcHdfUzBBMDZ5T0hXQ1BDTQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQbEl3NjBGUHVWaXh5djVmMUlYNU9OYkNjbzB2SHdtTjBFYUpIMGR3WVV4YlF1TTVHTkF2eDhrV1h5TVpuYWloSmRkcWtYNDczdThSOVlYV1p6M0ZWczhFcDdtNTZoMDZhZHlobGo2ZEhmZlNTMTRiV2ZkcFlZeUpLa1RvcVNQbmNwZ3lIQ3ZueW82QVpVLTROaUFta054ejhRZWZNZXA2TDZic1lGWmFiemJmZFpDY3phc0tUcHdfUzBBMDZ5T0hXQ1BDTQ?oc=5", "title": "Die Bristol-Myers-Squibb-Aktie legt nach starken Q2-Zahlen und neuer Zahlung zu", "content_text": "Die Bristol-Myers-Squibb-Aktie legt nach starken Q2-Zahlen und neuer Zahlung zu", "date_published": "2026-08-14T11:43:53+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:e6793ea00b43a8209175c2cdffd939d23887d050c43a1a645355d97124e49d99", "url": "https://www.nasdaq.com/articles/fidelity-healthcare-etf-vs-ishares-pharma-fund-which-wins", "external_url": "https://www.nasdaq.com/articles/fidelity-healthcare-etf-vs-ishares-pharma-fund-which-wins", "title": "Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?", "content_text": "Key Points Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.37% fee for iShares U.S. Pharmaceuticals ETF. iShares' fund provides concentrated exposure to 56 pharmaceutical stocks, while Fidelity's holds 338 stocks across the broader healthcare sector. The iShares fund delivered a higher one-year total return of 60% as of Aug. 10, 2026.10 stocks we like better than Fidelity Covington Trust - Fidelity Msci Health Care Index ETF \u203a While Fidelity MSCI Health Care Index ETF(NYSEMKT:FHLC) provides broad healthcare exposure at a very low cost, iShares U.S. P", "date_published": "2026-08-14T11:35:01+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:c484bca261c4a3982a6bcdde85ebbdb5a9c73ae69d053fb4c1a65ad9f7354295", "url": "https://finance.yahoo.com/healthcare/articles/u-physical-therapy-announces-cfo-113000319.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-physical-therapy-announces-cfo-113000319.html", "title": "U.S. Physical Therapy Announces CFO", "content_text": "HOUSTON, August 14, 2026--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (\"USPH\" or the \"Company\") (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (\"IIP\"), today announced that Nchacha Etta will serve as the Company's Executive Vice President and Chief Financial Officer, effective as of September 1, 2026. Jason Curtis, the Company's Senior Vice President, Finance and Accounting, served as Interim CFO since April 24, 2026. Mr. Etta brings significant experience, most recently serving as Executive Vice Presi", "date_published": "2026-08-14T11:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ESL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ESL", "name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme", "sentiment_url": "https://sharemaestro.com/sentiment/75108957-e650-45aa-8204-341874bb73b6/"}]}}, {"id": "source:a70cae582178023f97c17d47a0839120926b87bdd694780e1f452e8d69dbcac0", "url": "https://finance.yahoo.com/healthcare/articles/mark-cuban-says-401-k-111500193.html", "external_url": "https://finance.yahoo.com/healthcare/articles/mark-cuban-says-401-k-111500193.html", "title": "Mark Cuban says your 401(k) is \u2018part of the cost of health care problem.\u2019 Do you dump Big Insurance and own your values?", "content_text": "Photo by Nicola Gell / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below. If your retirement savings are invested in a broad index fund, Mark Cuban says you may be helping America's largest health insurers put profits ahead of patients. \"If you own shares in a fund that owns any of the biggest insurance carriers, you are part of the cost of health care problem in this country,\" the billionaire entrepreneur wrote on X (1). Must Read Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 \u2014 6 ways to b", "date_published": "2026-08-14T11:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "UNH"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "UNH", "name": "UnitedHealth Group Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/f72c163c-734b-4be4-bacc-7fc3aa9e96fb/"}]}}, {"id": "source:4a3743dd6463ed105ffc9c1441902f440c6c025c3c9d0aedf7bd19fa086ad557", "url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "title": "Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is designed to integrate scientific capabilities with data and digital tools to support discovery and development of new medicines. This expansion adds another research hub to Amgen's global footprint and increases its geographic diversification in Asia. Amgen is not the only healthcare stock investing", "date_published": "2026-08-14T11:12:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AMG"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AMG", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/168fd802-fccc-4e50-a2bc-bc539b6e35a1/"}]}}, {"id": "source:b8949dc9667dcce383f343bbc7bf9b59ebcb2d5d88a8a384fafd3899095259d3", "url": "https://www.nasdaq.com/articles/schd-vs-hdv-which-dividend-etf-better-buy-investors", "external_url": "https://www.nasdaq.com/articles/schd-vs-hdv-which-dividend-etf-better-buy-investors", "title": "SCHD vs. HDV: Which Dividend ETF Is the Better Buy for Investors?", "content_text": "Key Points The Schwab U.S. Dividend Equity ETF (SCHD) offers a slightly lower expense ratio and stronger recent returns than the iShares Core High Dividend ETF (HDV). HDV maintains a modestly more concentrated portfolio, with 75 holdings compared to SCHD's 103. Over the past five years, HDV has posted both stronger total returns and a less severe maximum drawdown than SCHD.10 stocks we like better than Schwab U.S. Dividend Equity ETF \u203a Income-seeking investors often gravitate toward established dividend funds to balance long-term capital appreciation with steady quarterly cash flow. Both the S", "date_published": "2026-08-14T11:11:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Capital return", "AMG"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AMG", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/168fd802-fccc-4e50-a2bc-bc539b6e35a1/"}]}}, {"id": "source:611c3c7e6d9823abbad41de0d6d89812c8b0824bb262f604ee9ed7202f98c020", "url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-102442230.html", "external_url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-102442230.html", "title": "Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses", "content_text": "Parnassus Investments, an investment management company, released the \"Parnassus Core Equity Fund\" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as well as the fund's lack of Energy exposure, while Financials and Health Care detracted. The fund is positioning for long-term growth through AI infrastructure, semiconductors, electrification and industrial automation, while", "date_published": "2026-08-14T10:24:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:483dae81a8645750f94d73ba0194dddd2330f8746335755914527985d64a5d07", "url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Stock index futures largely flat after S&P 500 closes at record high", "content_text": "[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) -0.24%. The S&P 500 reached another intraday record on Thursday as investors weighed July producer prices, which showed wholesale inflation was unchanged from the previous month. Investors will turn to July retail sales data at 8:30 a.m. ET for fresh clues on consumer ", "date_published": "2026-08-14T08:11:29+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Macro sensitivity", "BSX", "AFW"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}, {"symbol": "AFW", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9ffd5a89-eca6-4387-b5de-5a4a4ccc2d17/"}]}}, {"id": "source:cf8f8e2e6dfcace0e6fe8f5af3d77937351bfb2e3ce92051161d225e3ad41307", "url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "external_url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "title": "Envetec Appoints Patrick S. Jones as Independent Director", "content_text": "Envetec Senior Thermo Fisher Scientific executive brings nearly 30 years of healthcare and commercial leadership to support Envetec's global expansion Patrick S. JonesPatrick S. Jones, President of Thermo Fisher Scientific's Clinical Diagnostics Division and independent director of Envetec Sustainable Technologies BIRDHILL, Ireland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Envetec Sustainable Technologies Limited (Envetec), a leading sustainability innovator in clean technology for healthcare and life sciences, today announced the appointment of Patrick S. Jones, president of Thermo Fisher Scientific", "date_published": "2026-08-14T07:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:e142f91199ddc701efe333aa5e8027026f2517e3c090202450a3265d89e820a2", "url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "title": "Bekaert: Update on the Share Buyback Program and the Liquidity Agreement", "content_text": "Bekaert Update on the Share Buyback Program and the Liquidity Agreement Period from 6 August 2026 to 12 August 2026 Share Buyback Program On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to \u20ac 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 6 August 2026 to 12 August 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 56 000 shares. The table below provides an overview of the transactions under th", "date_published": "2026-08-14T06:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "BAYN"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/51239ea0-c40c-4626-8574-e77021366c47/"}]}}, {"id": "source:7c89340fa6041bf9ee98102a217dbed4be3be36a863f3dd727800eb04c101d76", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPQlJWQzk0bENuazV5bGJZT0ExT0pBdHhpMEFETGl3QnEtZk40bFVsc0U0dzdIakVnTFNVclEtMXFLMGJwUlptM3Nha1hpMmdOLTdYNG1yRVFvV0JwU2VQWlV4cmJEQjA4dW9zby1uTFNYZXF4QXhUN3lUOFJkalQ2UXFuX1F1WGZqMjloSW1oa3NmSEktclhNMnNHbDhqOGJtWnQzLUFaT0lySFQ0b2RCWWRsdnI4cGhzaWZzMmMybkJrVktGbjdzOWZiWndmb05Ick1B?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPQlJWQzk0bENuazV5bGJZT0ExT0pBdHhpMEFETGl3QnEtZk40bFVsc0U0dzdIakVnTFNVclEtMXFLMGJwUlptM3Nha1hpMmdOLTdYNG1yRVFvV0JwU2VQWlV4cmJEQjA4dW9zby1uTFNYZXF4QXhUN3lUOFJkalQ2UXFuX1F1WGZqMjloSW1oa3NmSEktclhNMnNHbDhqOGJtWnQzLUFaT0lySFQ0b2RCWWRsdnI4cGhzaWZzMmMybkJrVktGbjdzOWZiWndmb05Ick1B?oc=5", "title": "Die Fresenius-Aktie steigt nach erh\u00f6hter Prognose und R\u00fcckenwind von UBS", "content_text": "Die Fresenius-Aktie steigt nach erh\u00f6hter Prognose und R\u00fcckenwind von UBS", "date_published": "2026-08-14T06:09:36+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "FRE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FRE", "name": "Fresenius SE & Co. KGaA", "sentiment_url": "https://sharemaestro.com/sentiment/e78ad1fc-5039-4de9-914c-0a939a9dc7dc/"}]}}, {"id": "source:628df1dfc51b43eaf5176f665aa8074ea9d077a0712fc5bd8d80d1a4d67c31c5", "url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "title": "AFARAK GROUP: INTERIM REPORT H1 2026", "content_text": "Afarak Group SE 07:00 London, 09:00 Helsinki, 14 August 2026 - Afarak Group SE (\"Afarak\" or \"the Company\") (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026 H1/26 H1/25 2025 Revenue EUR million 57.1 77.1 141.3 EBITDA EUR million 1.6 6.9 -0.2 EBIT EUR million 0.5 5.9 -2.6 Earnings before taxes EUR million 0.1 3.4 -7.5 (Loss) / Profit for the period EUR million -0.7 2.4 -8.9 Earnings per share EUR 0.00 0.01 -0.03 EBITDA margin 2.8% 9.0% -0.2 EBIT margin 0.8% 7.7% -1.8 Earnings margin 0.2% 4.5% -5.3 Personnel (end of period) 625 613 626 FIRST HALF 2026 HIGHLIGHTS The Group recorded an ", "date_published": "2026-08-14T06:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYN"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/51239ea0-c40c-4626-8574-e77021366c47/"}]}}, {"id": "source:fce52fb7cca567794e99dc39a7fad5d38dceb11c6c53422cd19d89d4a898a787", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQakswQ0YtZ0F2OC03WEhyN3lqenIwbFpuaHlkWG12RjNzeHZYYTBjblUtMFNyTU1va0owaWVZODJ0RWFGZVJ5YjBscjhkT1dkbzFTV0NyYTBxQ3RqbXItRERfbjBrME54NXpRTF9Vbm1XdHAwM2NJRmkyOThMWG44cHphNERhZFJucjNjTEVSRkEtdDc4TUtJU1BPOFYtb1dQSmR5S0t6U0hRUEFnV1lITTBSUS1ZZENNNlp3Tk5jRm5VV0twYlUwQ2FJV0FqYzA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQakswQ0YtZ0F2OC03WEhyN3lqenIwbFpuaHlkWG12RjNzeHZYYTBjblUtMFNyTU1va0owaWVZODJ0RWFGZVJ5YjBscjhkT1dkbzFTV0NyYTBxQ3RqbXItRERfbjBrME54NXpRTF9Vbm1XdHAwM2NJRmkyOThMWG44cHphNERhZFJucjNjTEVSRkEtdDc4TUtJU1BPOFYtb1dQSmR5S0t6U0hRUEFnV1lITTBSUS1ZZENNNlp3Tk5jRm5VV0twYlUwQ2FJV0FqYzA?oc=5", "title": "Die Novo-Nordisk-Aktie bleibt nach verhaltener Q2-Entwicklung unter dem Konsenskursziel", "content_text": "Die Novo-Nordisk-Aktie bleibt nach verhaltener Q2-Entwicklung unter dem Konsenskursziel", "date_published": "2026-08-14T05:20:21+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "NOV"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOV", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/99663662-e62d-4669-8f9e-ac0c78084f2f/"}]}}, {"id": "source:7a3ca7923616fe6725d707ca6208a1fb2f4a69afa38f5bf33c43bcdb42459ae8", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUmQtaXY4VFNISWRsOE9wU1JEZlU3TUkzaF9WeHhLMzFfVkxlaS1kZnB3UG5yTWdjcndXQUJyX3B5TGwzWWlGTmNrWm5vbXRqLWtnR1BqT25XNjhxZXpsT2pnN0xTamR1b2lVWTNRZnBvcXI1blYxeFdOSm1vS2huUG5hUTN4cmJwQlNlaDdTMFh2UW9kZjA5S2FyX0NfaGlJd3o4Yi1LWHVZbnN6OW1nUURmUkwtSEl0WHJiMzRudw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUmQtaXY4VFNISWRsOE9wU1JEZlU3TUkzaF9WeHhLMzFfVkxlaS1kZnB3UG5yTWdjcndXQUJyX3B5TGwzWWlGTmNrWm5vbXRqLWtnR1BqT25XNjhxZXpsT2pnN0xTamR1b2lVWTNRZnBvcXI1blYxeFdOSm1vS2huUG5hUTN4cmJwQlNlaDdTMFh2UW9kZjA5S2FyX0NfaGlJd3o4Yi1LWHVZbnN6OW1nUURmUkwtSEl0WHJiMzRudw?oc=5", "title": "Die Evotec-Aktie f\u00e4llt nach Halbjahreszahlen und gekappter EBITDA-Guidance", "content_text": "Die Evotec-Aktie f\u00e4llt nach Halbjahreszahlen und gekappter EBITDA-Guidance", "date_published": "2026-08-14T05:05:49+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:0900c281a1b7e54999dfd196bbfe90a2a2a5cb52fdbe999e1d2a91793c625390", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "title": "Pfizer and Valneva\u2019s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency", "content_text": "Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR \"Vaccine Ag", "date_published": "2026-08-14T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE", "AYJ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}, {"symbol": "AYJ", "name": "Valneva SE", "sentiment_url": "https://sharemaestro.com/sentiment/72be05a1-645b-4461-92f2-b776ddee3ee3/"}]}}, {"id": "source:6d07e1170c1c7e05d704e304386b7fd0cec05076d2d3b1dd36866710208c5f2d", "url": "https://finance.yahoo.com/healthcare/articles/cvs-health-cvs-rolls-pbm-031718282.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cvs-health-cvs-rolls-pbm-031718282.html", "title": "CVS Health (CVS) Rolls Out New PBM Tools As Employer Trust Grows", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. CVS Health (NYSE:CVS) reports that employers show higher trust in pharmacy benefit managers to manage drug costs and access to complex treatments, according to a new CVS Caremark survey. The company is rolling out new digital tools for its PBM clients to manage pharmacy benefits and monitor prescription spending. CVS is expanding coverage for biosimilars and GLP-1 therapies across its pharmacy network with a focus on afforda", "date_published": "2026-08-14T03:17:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CVS"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/afaaf5cc-91b6-47c9-b6f2-91df86e7410b/"}]}}, {"id": "source:fe57a5427a6ee73cd86c5d8745e1445ab11aaa91307d49536ddca77ccfc1bd5d", "url": "https://finance.yahoo.com/markets/stocks/articles/top-5-analyst-questions-cvs-030900470.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/top-5-analyst-questions-cvs-030900470.html", "title": "The Top 5 Analyst Questions From CVS Health\u2019s Q2 Earnings Call", "content_text": "The Top 5 Analyst Questions From CVS Health's Q2 Earnings Call CVS Health's second quarter was marked by better-than-expected revenue and profit, but investor sentiment was dampened by rising concerns over sustainability of these results. Management cited strong performance across all business segments, particularly from specialty pharmacy and Medicare Advantage, as key drivers. CEO David Joyner acknowledged, \"the cumulative impact of these actions [in Aetna and Caremark] is starting to come through clearly in our results.\" However, management also highlighted pockets of pressure, such as ongo", "date_published": "2026-08-14T03:09:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CVS"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "CVS", "name": "CVS Health Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/afaaf5cc-91b6-47c9-b6f2-91df86e7410b/"}]}}, {"id": "source:73f203305b5d54485de2deb2823ca9b04af33338a782dd1b173d26623ce497c7", "url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "external_url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "title": "Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?", "content_text": "Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and other negatives, it makes sense why Wall Street isn't liking these merger rumors.10 stocks we like better than Bristol Myers Squibb \u203a In recent weeks, two pharmaceutical stocks, AstraZeneca(NYSE: AZN) and Bristol Myers Squibb(NYSE: BMY), have become the subject of merger rumors. At the start of the m", "date_published": "2026-08-14T02:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:2119559983d88f54fed2f9b6de7ae9cd6c9c03584d4dbac9d637eb5c0a7d098a", "url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "external_url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "title": "Philips (ENXTAM:PHIA) Expands Open Monitoring Ecosystem And Launches Postpartum Support Tool", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Koninklijke Philips (ENXTAM:PHIA) announces new collaborations to expand its open monitoring ecosystem and connected care offerings. The company introduces the Philips Avent Share the Care Connector to support postpartum mothers with digital tools and guidance. Philips works with health technology partners to extend continuous and out of hospital patient monitoring capabilities. The Share the Care Connector is launched in co", "date_published": "2026-08-14T00:16:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "PHI1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHI1", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/1cc4de78-0344-4bf2-8f9e-a385142353b4/"}]}}, {"id": "source:6d94a2828794f443fb7600fc36fdf927e9d2536c40861e5a870a9d6ffbb4958c", "url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "title": "Could Danaher Corporation (DHR)\u2019s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?", "content_text": "When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower in response. That drop immediately spilled over to Bio-Rad Laboratories, Inc. (NYSE:BIO), holder of a $5 billion strategic stake in Sartorius, sending Bio-Rad shares down about 1% in early New York trading.", "date_published": "2026-08-14T00:13:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DAP", "SRT3", "SRT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}, {"symbol": "SRT3", "name": "Sartorius Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/dcfaaded-82d3-4d3a-8310-ecd8306b2a4e/"}, {"symbol": "SRT", "name": "Sartorius Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/a04c198e-398c-454e-a1eb-a517deaf4eef/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "GE9"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GE9", "name": "GENMAB AS                     N", "sentiment_url": "https://sharemaestro.com/sentiment/ffbb4876-1d5e-482e-9cbc-952a406eec44/"}]}}, {"id": "source:225e5f3f54f2c0dab1dc5a139488f4dafc45871f56f0a63f77d03bb53f409820", "url": "https://finance.yahoo.com/healthcare/articles/elevance-health-elv-still-bargain-231418886.html", "external_url": "https://finance.yahoo.com/healthcare/articles/elevance-health-elv-still-bargain-231418886.html", "title": "Is Elevance Health (ELV) Still A Bargain After A 38% Gain?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Elevance Health has delivered a 37.6% gain over the past year, yet current valuation checks still lean on the side of the stock looking inexpensive rather than stretched. For investors, that creates a pricing debate around how much of the company's recent health data partnerships and care model initiatives is already reflected in today's US$398.22 share price. Over the last 12 months Elevance Health is up 37.6%. This puts recent shareholders in a comfort", "date_published": "2026-08-13T23:14:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "A58"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "A58", "name": "Elevance Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1d5bf969-2db0-49f7-bd02-ec9dd329dcd9/"}]}}, {"id": "source:e9910ce59642be6aa999514f06aedcc53452cf2fd331fe433b68b6c9c6898454", "url": "https://finance.yahoo.com/markets/stocks/articles/mlp-se-wbo-mlp-q2-230932085.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/mlp-se-wbo-mlp-q2-230932085.html", "title": "MLP SE (WBO:MLP) (Q2 2026) Earnings Call Highlights: Record Revenue and EBIT Fuel Optimistic Outlook", "content_text": "This article first appeared on GuruFocus. Total Revenue: Increased by 10% to a record EUR583 million in the first half of 2026. EBIT: Reached a new record high of EUR64 million in the first half of 2026. Revenue by Competence Field: Property & Casualty grew 12%, Wealth grew 11%, and Life & Health was slightly above the previous year's levels. Assets Under Management: Increased to a new record level of EUR68.8 billion. Non-life Insurance Premium Volume: Reached a new record high of EUR865 million. Equity: Increased from EUR585 million to EUR589 million compared to the 2025 balance sheet date. R", "date_published": "2026-08-13T23:09:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYN"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/51239ea0-c40c-4626-8574-e77021366c47/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e87ae051-5953-43aa-97e5-132814dcdeea/"}]}}, {"id": "source:f24688ac4b49aeeb0e4d88979e328a0a6e96e368502d0f733fb24b04fa9f7824", "url": "https://finance.yahoo.com/healthcare/articles/viatris-vtrs-selling-tyrvaya-could-230317847.html", "external_url": "https://finance.yahoo.com/healthcare/articles/viatris-vtrs-selling-tyrvaya-could-230317847.html", "title": "Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?", "content_text": "According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent sales milestone payments. Expected to close in the second half of 2026, the transaction transfers a dry eye disease treatment approved in the U.S., China, and Taiwan to a specialized ophthalmic player, allowing Viatris to streamline its portfolio.Could Danaher Corporat", "date_published": "2026-08-13T23:03:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VIA", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}, {"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:43fb835313f01faeda6bcafaf7ebbaf8394c86b41d24f6a7ca130156aae1ed4f", "url": "https://finance.yahoo.com/healthcare/articles/could-gsk-plc-gsk-pipeline-220109388.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-gsk-plc-gsk-pipeline-220109388.html", "title": "Could GSK plc (GSK)\u2019s Pipeline Acceleration Unlock a New Growth Era?", "content_text": "On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm's total Q2 turnover reached \u00a38.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to \u00a32.80 billion and Core EPS rose 9% CER to 50.5p. Growth was primarily fueled by double-digit gains in Specialty Medicines (+14% CER to \u00a33.8 billion) and robust momentum in Vaccines (+8% CER to \u00a32.3 billion). However, Total operating profit dropped 75% CER to \u00a3481 ", "date_published": "2026-08-13T22:01:09+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GS71"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GS71", "name": "GSK plc", "sentiment_url": "https://sharemaestro.com/sentiment/067e7168-cebe-45f9-8666-2b4a34da7f50/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GIS"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GIS", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e3c6982e-ae5c-4ff3-adc6-34eca37512f0/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Product Image (Photo: Bristol Myers Squibb)ZENBEXUS\u2122 (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb's targeted protein degradation platform PRINCETON, N.J., August 13, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has a", "date_published": "2026-08-13T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:97abb1479c491d8ba318966da99fb82d37b173bee51f2fb9b122d1e372a8b78a", "url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-reports-second-quarter-204400492.html", "external_url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-reports-second-quarter-204400492.html", "title": "Atrium Therapeutics Reports Second Quarter 2026 Financial Results", "content_text": "-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (\"Atrium,\" \"Atrium Therapeutics,\" or the \"Company\"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Inv", "date_published": "2026-08-13T20:44:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:0307dd02aa0975f7f8405c50db19c72c2cdf264792b461807601c006f7de5fed", "url": "https://finance.yahoo.com/healthcare/articles/assembly-biosciences-reports-second-quarter-200000615.html", "external_url": "https://finance.yahoo.com/healthcare/articles/assembly-biosciences-reports-second-quarter-200000615.html", "title": "Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates", "content_text": "Assembly Biosciences, Inc. \u2013 Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) \u2013 \u2013 Completed $115 million gross financing to support advancement of pipeline programs through key development milestones \u2013 \u2013 GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 \u2013 \u2013 Cash runway projected into 2029, including first $75 million Gilead collaboration extension payment due in Q4 2026 \u2013 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE", "date_published": "2026-08-13T20:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GIS"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GIS", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e3c6982e-ae5c-4ff3-adc6-34eca37512f0/"}]}}, {"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:8aa075b08cd3ce838ce32b3f745f82e6751a927cb2ff79d1011d3595c0792005", "url": "https://finance.yahoo.com/healthcare/articles/qiagen-qgen-beat-own-guidance-191825052.html", "external_url": "https://finance.yahoo.com/healthcare/articles/qiagen-qgen-beat-own-guidance-191825052.html", "title": "Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?", "content_text": "Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own outlook. For a diagnostics and life sciences supplier still working through the loss of discontinued product lines, beating a cautious bar is one thing. What happens next, as management leans on a stack of new launches to carry the back half of the year, is the more interesting question.HPE Price Target Raised to $28 as Corporate AI Spending Accelerates Bull Ca", "date_published": "2026-08-13T19:18:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "QIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "QIA", "name": "Qiagen N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/c7c283ff-2c34-4ea9-b775-1ba4cd1e9c0c/"}]}}, {"id": "source:0f4f9816ac288bbbdb5a400fe337aa24cdb4d2657cfc0feb0472fa5db9f39220", "url": "https://finance.yahoo.com/healthcare/articles/gene-therapy-remains-top-mind-185900886.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gene-therapy-remains-top-mind-185900886.html", "title": "Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success", "content_text": "Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, while Spherix patient research reveals continued interest in the modality. Exton, PA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The hemophilia gene therapy market is contracting commercially, but physician and patient interest in the modality has not disappeared. Recent commercial developments, including the discontinuation of BEQVEZ\u00ae (Pfizer), withdrawal of ROCTAVIAN\u00ae (BioMarin), and supply challenges for HEMGENIX\u00ae (CSL Behring), have narrowed the available gene ", "date_published": "2026-08-13T18:59:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}, {"id": "source:089743f13550a0eb23280103b41e8105a37f127064163297e8ab53eb57fa0359", "url": "https://finance.yahoo.com/technology/ai/articles/michael-burry-sends-fresh-ai-184329662.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/michael-burry-sends-fresh-ai-184329662.html", "title": "Michael Burry Sends Fresh AI Warning on Nebius, Micron and Oracle", "content_text": "This article first appeared on GuruFocus. Michael Burry (Trades, Portfolio) has increased bearish positions tied to artificial intelligence and semiconductor stocks, while adding to selected long holdings, according to a Wednesday Substack post. Warning! GuruFocus has detected 3 Warning Signs with MU. Is MU fairly valued? Test your thesis with our free DCF calculator. Burry added to his short positions in Nebius Group (NASDAQ:NBIS), Micron Technology (NASDAQ:MU), Oracle (NYSE:ORCL) and the iShares Semiconductor ETF (NASDAQ:SOXX). The investor said he added to his NBIS position at $247, MU at $", "date_published": "2026-08-13T18:43:29+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOV", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOV", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/99663662-e62d-4669-8f9e-ac0c78084f2f/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:f687ca88d44b8346269757b2f5464410caf7e9eea843f7769ef30c66c174f505", "url": "https://www.nasdaq.com/articles/viatris-vtrs-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/viatris-vtrs-q2-2026-earnings-call-transcript", "title": "Viatris (VTRS) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- $3.8 billion, representing 3.5% operational growth year over year driven by strength in Greater China and complex generics in North America.Adjusted EBITDA -- $1.2 billion, reflecting an 8% operational increase versus the prior year due to operating leverage and cost discipline.Adjusted EPS -- $0.69, a 9% operational in", "date_published": "2026-08-13T18:13:22+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IUI1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "IUI1", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/dde42408-63d5-4895-a259-d88509f63e45/"}]}}, {"id": "source:352a0f3761594e28dc3c1d362f7b538ee156b891d3026295e72946763c29c5ee", "url": "https://finance.yahoo.com/markets/stocks/articles/syk-worth-buying-growth-improves-174900186.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/syk-worth-buying-growth-improves-174900186.html", "title": "Is SYK Worth Buying as Growth Improves but Execution Risks Persist?", "content_text": "Stryker Corporation SYK presents a growth-versus-execution decision. Second-quarter sales and earnings improved sharply as the company recovered from its first-quarter cybersecurity disruption, while margins expanded and demand remained broad. The case is not risk-free. Cyber remediation costs, vascular supply constraints and acquisition execution still matter. For investors, the question is whether Stryker's improving fundamentals and product pipeline justify adding exposure before those operating issues are fully resolved. SYK's Growth Case Is Stronger Than Its Risk Profile Stryker delivered", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "IUI1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "IUI1", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/dde42408-63d5-4895-a259-d88509f63e45/"}]}}]}